China Trademark Classes for Medical Device Companies: Class 10, NMPA & OEM Manufacturing Risks

For international medical device companies, entering the Chinese market involves a critical misunderstanding that can be more damaging than in any other industry. Many manufacturers assume that obtaining NMPA (National Medical Products Administration) product registration automatically secures their brand rights. It does not. NMPA registration and China trademark registration are entirely separate legal systems — one governs product safety and market access, the other governs brand ownership and enforcement. A company can hold full NMPA approval for a Class III implantable device yet have zero legal right to stop a competitor or distributor from using its brand name in China.

This is compounded by the fact that most medical device brands engage deeply with Chinese supply chains long before they ever sell to a Chinese hospital. OEM manufacturing agreements, distributor partnerships, and clinical trial collaborations all expose the brand to parties who can — and frequently do — file the trademark first. In an industry where brand reputation directly affects hospital procurement decisions, tender eligibility, and clinical trust, losing control of a trademark is not just a legal setback. It is a commercial exclusion from the market.

This article explains the trademark classes, filing strategies, and regulatory interface that medical device companies must understand before engaging with Chinese manufacturers, distributors, or regulatory authorities. It is based on real CNIPA practice and direct experience with medical device clients navigating the NMPA-trademark interface. For a complete reference of all CNIPA classes and their subclasses, see our China Trademark Classification List.

Regulatory Timeline: Why Trademark Protection Must Come First

The sequence of regulatory and commercial steps for medical device entry into China follows a predictable path. In nearly every case, trademark protection should begin before every other step.

The sequence matters. Trademark protection should begin before every other step in the regulatory and commercial timeline. Delaying filing until after NMPA approval, after OEM engagement, or after distributor agreements exposes the brand to registration by parties who encounter it earlier in the process. A pending CNIPA application is often sufficient to establish priority while the regulatory review is underway. For brands that have not yet begun the process, a professional trademark search can identify whether the brand name or its Chinese equivalent is already occupied before any filing or regulatory submission begins. Understanding China’s first‑to‑file system is essential to grasp why timing matters more than any other factor.

1. Why NMPA Registration Does Not Protect Your Brand

NMPA registration is a product-focused regulatory process. It evaluates safety, efficacy, and manufacturing quality for a specific medical device model. The NMPA does not examine trademark rights, does not check whether the brand name on the device conflicts with a prior CNIPA registration, and does not confer any exclusive right to use that name in commerce.

A foreign manufacturer can receive NMPA approval for a device branded “MediScan” and simultaneously discover that a local entity has registered “MediScan” as a trademark in Class 10 for medical devices. The NMPA registration does not provide grounds to cancel that trademark, block its use, or reclaim the name. The brand owner, despite having invested months and significant capital in regulatory approval, now faces a choice: rebrand, purchase the mark, or litigate.

The practical consequence is that trademark filing must precede or run parallel to the NMPA process — not follow it. A pending CNIPA application is often sufficient to establish priority while the regulatory review is underway. Delaying trademark filing until after NMPA approval is the single most common and costly timing error we see medical device companies make.

2. Core Trademark Classes for Medical Device Companies

Class 10 — Medical and surgical apparatus

This is the primary class for medical devices. It covers surgical instruments, diagnostic equipment, orthopaedic implants, infusion pumps, patient monitors, dental apparatus, and veterinary devices. Class 10 is non-negotiable for any company selling physical medical hardware in China. However, CNIPA subdivides Class 10 into multiple similar groups — a registration for “surgical instruments” does not automatically cover “diagnostic imaging apparatus” or “implantable prostheses.” Each product category must be individually specified. For a complete overview of how such subdivisions work across all industries, see our guide on China Trademark Classes and the China Subclass System. For subclass-level details within Class 10, refer to the Class 10 subclasses PDF.

Class 9 — Medical software, diagnostic AI, wearable monitors

Modern medical devices are increasingly software-driven. If your device includes downloadable diagnostic software, an AI-powered imaging analysis tool, a wearable patient monitor with a companion app, or any standalone medical software application, Class 9 protection is required. A Class 10 registration for the physical device does not protect the software that runs it — and as hospitals increasingly evaluate devices based on software capability, this gap can be commercially significant. See the Class 9 subclasses PDF for precise subclass mapping.

Class 42 — Medical SaaS platforms, cloud diagnostic services, R&D

If you provide a cloud-based medical imaging platform, a telemedicine SaaS solution, a hospital data management system, or contract R&D services for medical device development, Class 42 is where those services are protected. The line between Class 9 (downloadable medical software) and Class 42 (cloud-based medical services) mirrors the broader software classification issue, but with added regulatory complexity — the NMPA may classify certain software functions as medical devices themselves, adding a layer of regulatory scrutiny that intersects with trademark classification. For subclass details, see the Class 42 subclasses PDF.

Class 44 — Medical and healthcare services

Class 44 covers medical clinics, diagnostic centres, telemedicine services, and health screening services. If your business model includes operating branded diagnostic facilities, offering remote consultation services, or running clinical testing centres in China, Class 44 protection is necessary. A medical device sold under a particular brand does not automatically protect that brand for the services that use the device.

Class 35 — Retail, distribution, and procurement marketing

Class 35 covers retail services for medical devices, online medical equipment sales platforms, and business management services including tender preparation and hospital procurement marketing. For companies that participate in Chinese hospital bidding processes or sell through online medical device marketplaces, Class 35 provides essential coverage that product classes alone do not offer.

3. Why Class 10 Alone Is Usually Not Enough

A medical device company’s business model — not just its product — determines the correct trademark class strategy. A single class filing almost never provides full protection. The table below maps common medical device business models to the classes that should be included in any China trademark application.

This multi-class approach reflects how CNIPA examines each class independently. Without it, even a fully NMPA-registered device brand can lose control of its software component, its cloud platform, its hospital procurement identity, or its Chinese brand name — all of which are separately exploitable by third parties. For guidance on selecting the correct goods and services within each class, see How to Correctly Select China Trademark Classification Subclasses.

4. Manufacturing in China Without Selling in China

A significant portion of the world’s medical devices are manufactured, assembled, or packaged in China by brands that have no current intention of selling into the Chinese market. These companies contract with factories in Suzhou, Shenzhen, or Tianjin for OEM production, with all output destined for export to the US, Europe, or other markets. Many assume that because they do not sell in China, they do not need a Chinese trademark. This assumption is incorrect and carries specific risks.

A Chinese factory with access to a brand’s specifications, packaging designs, and regulatory documentation can file a trademark application in Class 10 in its own name. Once registered, the factory can record the trademark with China Customs, potentially blocking the brand owner’s own exports on the grounds of trademark infringement. Even if the brand owner never intends to sell a single unit in China, a factory-owned trademark can disrupt the export supply chain and become leverage in commercial negotiations.

A Chinese trademark registration in the brand owner’s name — filed before any technical documentation is shared with the manufacturing partner — prevents this scenario. The registration does not require the brand to sell in China. It simply establishes ownership and priority, ensuring that the brand, not the factory, controls the trademark in the country where the products are made. This is a foundational element of any China Trademark Registration strategy for medical device companies, regardless of their commercial plans for the Chinese market. For a deeper understanding of factory-related risks, see our guide on China Trademark OEM Risks.

5. When Software and Devices Must Be Filed Together

The convergence of hardware and software in modern medical devices creates a classification challenge. Consider a portable ultrasound system sold with a downloadable AI image analysis application and an optional cloud storage service. This single product ecosystem involves:

Filing only in Class 10 for “medical imaging apparatus” leaves the software, cloud services, and diagnostic services entirely unprotected. A competitor could register the same brand in Class 9 for “medical imaging software” and Class 42 for “cloud-based medical data storage,” then legally market a software platform under that name — creating confusion in exactly the hospital procurement environments where the original device manufacturer operates.

6. OEM Manufacturing Risks: File Before Production

A substantial portion of the world’s medical devices are manufactured, assembled, or packaged in China — even for brands that never sell into the Chinese market. Suzhou, Shenzhen, and Tianjin are major hubs for medical device contract manufacturing. In these relationships, the Chinese factory has full access to the brand, product specifications, packaging designs, and regulatory documentation long before the first unit ships.

Factory trademark squatting in the medical device sector is more damaging than in consumer goods. A factory that registers a client’s trademark in Class 10 can disrupt the supply chain by filing customs recordals that block the brand owner’s own exports, or by demanding exclusivity or payment as a condition of continued manufacturing. Because medical devices often have long qualification cycles and validated manufacturing processes, switching factories is far more difficult than in consumer industries, giving the squatting factory significant leverage.

Trademark filing must be completed before any technical documentation, packaging specifications, or manufacturing agreements are shared with a Chinese OEM partner. This applies equally to brands that manufacture solely for export and have no current intention of selling in China. If you discover that your brand has already been registered by a third party, see our remedy series for available legal actions and negotiation strategies.

7. Distributor and Agent Trademark Squatting

Medical device distribution in China relies heavily on local partners who manage relationships with hospital procurement departments, tender processes, and provincial health authorities. These distributors often handle regulatory submissions, product registration renewals, and after-sales service — giving them deep visibility into the brand and substantial control over market access.

A common pattern: a foreign medical device company appoints a Chinese distributor. The distributor, seeking to protect its commercial position or to gain bargaining leverage, registers the brand’s trademark — including its Chinese transliteration — in Class 10 and Class 35. When the foreign company later attempts to switch distributors, expand its direct sales team, or renegotiate terms, it discovers the distributor owns the trademark. The brand cannot be used with a new distributor without the original distributor’s consent.

The solution is always to file and register the trademark before signing any distribution agreement. Chinese trademark ownership must remain with the brand owner, with the distributor operating under a formal trademark licence. This maintains the brand owner’s freedom to change distribution arrangements without losing the right to its own name in the Chinese market. This pattern is a direct consequence of China’s first‑to‑file principle, where the earliest filer gains priority regardless of prior use outside China.

8. Hospital Procurement and the Brand-Tender Connection

In China’s hospital procurement system, brand identity is not merely marketing. It is directly embedded in the tender and purchasing process. Hospital bidding documents frequently require the manufacturer’s registered trademark information. If the trademark is registered under a distributor’s name rather than the manufacturer’s, the manufacturer may be unable to participate directly in tenders.

More critically, if a local entity has registered the brand in China and that entity is not the manufacturer, the manufacturer may appear to be an unauthorised supplier of its own products. This creates confusion in procurement evaluations and can disqualify the manufacturer from bidding in favour of the trademark holder — who may have no manufacturing capability but owns the legal right to the brand name in China.

A properly registered trademark in the manufacturer’s name is a prerequisite for direct participation in Chinese hospital procurement. Without it, the manufacturer is dependent on the trademark holder for market access — a strategically dangerous position.

9. Chinese Brand Name Strategy for Medical Devices

Chinese brand names are ubiquitous in the medical device sector. Doctors, procurement officers, and clinical staff almost exclusively use Chinese names when referring to foreign medical equipment. These names often develop organically — a phonetic approximation of the original brand, a description of the device’s function, or a term coined by the first distributor to sell the product.

If the foreign manufacturer does not proactively create and register an official Chinese name, the de facto Chinese name will be registered by whoever acts first. This could be a distributor, a competitor, or an unrelated third party. Once registered, the Chinese name can be used to market compatible consumables, replacement parts, or competing devices under a name that clinicians already associate with the original brand.

Registering a Chinese Trademark Name early — a phonetic transliteration, a descriptive equivalent conveying precision or care, or both — and filing it in Classes 10, 9, 42, 35, and 44 as applicable, is essential to controlling brand identity across the full spectrum of device sales, software, services, and procurement.

10. Filing Strategy by Business Type

11. Common Mistakes Medical Device Companies Make

• Waiting until after NMPA registration to file a trademark — the regulatory approval process does not protect the brand, and delays create a window for squatting.
• Filing only in Class 10 — software, cloud services, and medical services remain unprotected, leaving the full product ecosystem exposed.
• Not registering a Chinese brand name — clinical staff and procurement officers create and use a Chinese name regardless; if unregistered, it will be claimed by a third party.
• Sharing brand materials with OEM factories before filing — factory access to packaging and specifications precedes trademark filing in many cases, and the factory files first.
• Allowing distributors to file the trademark — the most damaging and common pattern in medical device trademark disputes in China.
• Assuming no trademark is needed if not selling in China — OEM factories can register the mark and disrupt exports, regardless of the brand’s commercial plans.

For additional context on market entry risks, explore our Foreign Brand China Entry Legal Risk Series.

12. FAQ

13. Conclusion

Medical device companies face a trademark environment in China that is more complex than in any consumer-facing industry. The separation between NMPA regulatory approval and CNIPA trademark rights, the deep involvement of OEM manufacturers and distributors, and the direct link between brand ownership and hospital procurement access create risks that generic trademark advice does not address. A properly structured filing strategy — covering devices, software, services, and a Chinese brand name, filed before any partner engagement — is the foundation for commercial control in the Chinese medical device market. For brands that manufacture in China without selling there, trademark registration is not optional. It is a supply chain safeguard as essential as any quality certification or regulatory approval.